Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection

Yao Hu | Hui Yu

Department of Infectious Diseases, Children’s Hospital of Fudan University, Shanghai, China

Correspondence
Hui Yu, Department of Infectious Diseases, Children’s Hospital of Fudan University, Shanghai 201102, China
Email: yuhui4756@sina.com

Received: 14 May, 2020
Accepted: 9 June, 2020

ABSTRACT
Chronic hepatitis B virus (HBV) infection caused by mother-to-child transmission (MTCT, also known as vertical transmission) during the perinatal period is a major public health problem worldwide. Despite the availability of the combined active-passive immunization with a hepatitis B vaccine and hepatitis B immunoglobulin after birth, about 9% of newborns are still infected with HBV, especially those born to hepatitis B e antigen (HBeAg)-positive mothers. Currently, the management of HBV infection during pregnancy remains controversial. This article briefly reviews the recent advances in the epidemiology of HBV, immunization against it, and management strategies in the third trimester.

KEYWORDS
Hepatitis B virus, Mother-to-child transmission, Immunization, Antiviral therapy

Epidemiology of hepatitis B virus infection
Hepatitis B virus (HBV) infection is a major public health concern worldwide. Chronic HBV infection is extremely harmful and is closely associated with the development of cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Globally, HBV infection is found in 30% and 45% of patients with liver cirrhosis and HCC, respectively. In China, the incidence of HBV infection is 60% and 80% in these patients, respectively. According to the World Health Organization, about two billion people are infected with HBV worldwide, more than 240 million of whom are chronically infected. In most cases, these infections are acquired during the perinatal period or in infancy or childhood, especially in countries and regions with a high prevalence of HBV. Even in countries and regions with low prevalence of HBV infections, the number of individuals infected with HBV during the perinatal period or infancy may account for more than one third of the total number of infections. The risk of chronic infection is related to the age at infection, and approximately 90% of infections acquired in the perinatal period or infancy become chronic, compared with 50% of those acquired under 3 years of age and 5% of those acquired in adulthood. The prevalence of chronic hepatitis B is high in China. A seroepidemiological survey of hepatitis B in 2006 showed that the prevalence of hepatitis B surface antigen (HBsAg) among the general population aged 1–59 years in China was 7.18%. It was estimated that there were about 93 million HBV carriers in China, including about 20 million patients with chronic hepatitis B. The Chinese Center for Disease Control and Prevention undertook a seroepidemiological survey of hepatitis B in the general population aged 1–29 years in 2014, which showed that the HBsAg prevalence rates in the subpopulations aged 1–4 years, 5–14 years, and 15–29 years were 0.32%, 0.94%, and 4.38%, respectively. Preventing mother-to-child transmission (MTCT) is the key to controlling HBV infection and reducing the

DOI: 10.1002/ped4.12205

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

©2020 Chinese Medical Association. Pediatric Investigation published by John Wiley & Sons Australia, Ltd on behalf of Futang Research Center of Pediatric Development.
incidence of related complications. The major routes of HBV infection are blood contact, MTCT, and sexual contact.\textsuperscript{15} With improvements in detection methods and the standardization of medical procedures, HBV transmission through blood transfusions and blood products has become less common. In contrast, MTCT has become a major transmission route—more than half of existing hepatitis B patients were infected through MTCT.\textsuperscript{14} An epidemiological survey showed that the prevalence of HBsAg among pregnant women in China was 5.49%. In the newborn infants of HBsAg- and hepatitis B e antigen (HBeAg)-positive mothers, the incidence of MTCT reached 7.1% despite the administration of a hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth.\textsuperscript{16}

There are three main MTCT routes: in utero, during labor, and during close contact with the mother after birth. Among these, transmission in utero and during labor are the commonest routes, and this explains the high failure rate of immunizing newborns to after birth.\textsuperscript{10,17,18} Preventing the MTCT of HBV infection should be based on its transmission mechanism, and the main measures taken are the antiviral treatment of mothers during pregnancy and the immunization of newborns after delivery.

**Postnatal immunization**

Hepatitis B vaccination within 24 hrs of birth can dramatically reduce perinatal HBV transmission.\textsuperscript{19} Since China introduced the hepatitis B vaccine into its national vaccination program in 1992, the prevalence of HBsAg has dropped significantly.\textsuperscript{20} Meta-analyses have suggested that the dual immunization of newborns born to HBsAg-positive mothers with a hepatitis B vaccine and HBIG can reduce the incidence of HBV infection and effectively prevent the MTCT of HBV infection.\textsuperscript{21-24} For newborns of HBsAg-positive mothers, especially those who are HBsAg- and HBeAg-positive, HBIG should be injected as early as possible within 24 hrs of birth (preferably within 12 hrs), at a dose of ≥ 100 IU. The first dose of a human hepatitis B vaccine (10 mg) from recombinant yeast should be administered at different locations and the second and third doses are administered at 1 and 6 months after the initial dose, which will effectively prevent MTCT.\textsuperscript{14,25-27}

The passive-active immunization of newborns with an HBV vaccine and HBIG can lower the HBV infection rate and effectively prevent vertical transmission. However, up to 25%–30% of newborns are still infected with HBV as a result of HBIG or vaccination failure, which may be related to intrauterine infections.\textsuperscript{10,28,29} The transplacental transmission of and intrauterine infection with HBV mainly occur in the third trimester, and the risk of MTCT correlates positively with maternal HBV-DNA loads.\textsuperscript{16,30,31} One study reported that when the serum HBV-DNA level in pregnant women exceeded $1.0 \times 10^8$ copies/mL, the incidence of intrauterine infection was as high as 9%, despite postnatal active and passive immunization of the newborns.\textsuperscript{32} MTCT is more likely to occur in newborns born to mothers with an HBV-DNA level of $> 1.0 \times 10^8$ copies/mL than in those born to mothers with less than an HBV-DNA level of $< 1.0 \times 10^8$ copies/mL. The risk of HBV infection is 8%–30% higher in the former.\textsuperscript{16,33-35} Therefore, preventing measures that are based on the combination of a hepatitis B vaccine with HBIG cannot fully meet clinical requirements. Pregnant women have abnormal immune elimination and liver function, which are harmful to themselves and their fetuses. Therefore, appropriate measures must be taken at the appropriate time in high-risk pregnant women.

**Antiviral therapy during pregnancy for HBsAg-positive mothers**

The maternal HBV-DNA level and HBeAg positivity are important factors affecting the MTCT of HBV infection. Without any intervention, the incidence of HBV infection in babies delivered to HBeAg-positive mothers is up to 95%. In contrast, if combined active-passive immunization with a hepatitis B vaccine and HBIG is given to newborns of HBsAg-positive mothers at birth, the incidence of MTCT is reduced to 3%–7%.\textsuperscript{22,36,37} In contrast, for newborns of HBeAg-positive mothers with high HBV-DNA loads, the incidence of MTCT can reach 8%–32% despite the application of combined active-passive immunization with a hepatitis B vaccine and HBIG at birth.\textsuperscript{31,32,38} Therefore, lowering the mother’s HBV-DNA level during pregnancy is particularly important in preventing MTCT.

A large number of clinical studies have explored the use of nucleosides as an antiviral treatment for mothers with high HBV-DNA viral loads during the second and third trimesters of pregnancy, in addition to combined active-passive immunization with a hepatitis B vaccine and HBIG.\textsuperscript{39-41} Nucleoside analogues currently approved by the U.S. Food and Drug Administration for anti-HBV therapy include telbivudine, tenofovir, and lamivudine.\textsuperscript{42-44} Telbivudine and tenofovir are class B drugs. Lamivudine is a class C drug and was the first nucleoside analogue approved in China. Animal experiments have shown that it has adverse effects on embryos, but it is safe and tolerated well in HIV-infected pregnant women.\textsuperscript{45}

Yu et al conducted a study of the efficacy and safety of lamivudine in preventing MTCT in 100 HBeAg-positive mothers whose HBV-DNA levels were $> 1.0 \times 10^6$ copies/mL (6.3 $\log_{10}$ IU/mL) between weeks 24 and 32 of pregnancy. Newborns in both groups (lamivudine group and placebo group) received combined hepatitis B vaccine and HBIG immunization after birth. The results showed that the MTCT rates were 0% and 7% in the lamivudine group and placebo group, respectively ($P < 0.05$).\textsuperscript{46}
An Australian observational study suggested that lamivudine has a low resistance barrier and that its use should be initiated in the third trimester of pregnancy and discontinued immediately after delivery. Twenty-one mothers with HBV viral loads of \(> 1.0 \times 10^7\) IU/mL received lamivudine for an average of 53 days, and after treatment, their viral loads decreased by an average of 2.6 \(\log_{10}\) IU/mL, although the HBV-DNA levels in four patients were still \(> 1.0 \times 10^7\) IU/mL. Viral mutations and reduced lamivudine sensitivity were observed in four mothers (19%). Therefore, the use of lamivudine in the third trimester of pregnancy may not be very effective and there is a risk of selective resistance. Lamivudine is no longer used as a first-line antiviral therapy in chronic hepatitis B patients because of its high resistance rate. Therefore, the use of lamivudine as an antiviral therapy during the third trimester of pregnancy requires careful evaluation.

Compared with lamivudine, telbivudine is a newer nucleoside analogue with better efficacy and a lower resistance rate. It specifically inhibits the DNA polymerase of HBV without any effect on the activity of human DNA polymerases and other human viruses. Many clinical studies have investigated the role of telbivudine in preventing MTCT.

An open study with a large sample size was conducted in 229 HBeAg-positive pregnant Chinese women whose HBV-DNA load was \(> 1.0 \times 10^7\) copies/mL. These mothers received telbivudine from week 20 to week 32 of gestation \((n = 135)\) or were untreated controls \((n = 94)\). All the infants in both arms received combined active-passive immunization after birth. Before delivery, the HBV-DNA loads decreased by \(1.0 \times 10^7\) copies/mL in the telbivudine-treated group, but showed no significant change in the control group. Seven months after delivery, the rate of HBsAg positivity was 0% in the babies born to the telbivudine-treated mothers and 8% in those born to the untreated mothers \((P = 0.002)\).

A meta-analysis included data from six clinical studies (a total of 576 pregnant women as subjects). The results showed that antiviral treatment with telbivudine in the third trimester of pregnancy safely and effectively prevented MTCT. However, it promoted the negative conversion of HBV-DNA and the normalization of alanine aminotransferase in HBV-infected mothers, at least to some extent.

In an observational study in China, 252 HBeAg-positive pregnant women with HBV-DNA loads of \(> 1.0 \times 10^7\) copies/mL commenced telbivudine treatment in gestational week 28 and continued until 4 weeks after delivery. The other 345 pregnant women, with similar baseline data, were not treated with antiviral therapy (and were the control group). The results showed that the MTCT rates were 0% and 2.84% in the telbivudine-treated group and control group, respectively \((P = 0.0002)\). Other studies have also suggested that telbivudine significantly and safely prevents the MTCT of HBV infection.

Tenofovir is a potent anti-HBV agent with a low incidence of drug resistance. It is recommended as the first-line anti-HBV drug in European and American guidelines. Many studies have reported the use of tenofovir for preventing MTCT. A retrospective study included 45 pregnant patients with HBeAg-positive chronic hepatitis B and HBV-DNA levels \(> 1.0 \times 10^7\) copies/mL, some of whom received tenofovir disoproxil fumarate (TDF) from week 18 to week 27 of gestation \((n = 21)\). The untreated pregnant patients acted as the controls \((n = 24)\). All infants received HBIG and recombinant HBV vaccine as active-passive immunization after birth. The MTCT rate was 0% and 8.3% in the TDF group and control group, respectively \((P = 0.002)\). No adverse events were observed in the TDF group.

The study of Greeup et al included 58 pregnant women who used TDF from gestational week 32 to 4–12 weeks after delivery. The control group contained 20 pregnant women who received no intervention. The results showed that TDF effectively reduced the maternal HBV viral load by \((3.64 \pm 0.9) \log_{10}\) IU/mL and markedly lowered the MTCT of HBV infection, which was 2% and 20% in the TDF group and untreated group, respectively.

The efficacy and safety of maternal TDF treatment in reducing perinatal HBV transmission were also evaluated in a prospective, multicenter trial that enrolled 118 HBsAg- and HBeAg-positive pregnant women with HBV-DNA \(> 7.5 \log_{10}\) IU/mL. The mothers received no medication \((control\ group, n = 56)\) or TDF \((TDF\ group, n = 62)\) from week 30–32 of gestation until 1 month postpartum. At delivery, the TDF group had lower maternal HBV-DNA levels than the controls \([(4.29 \pm 0.93)\) versus \((8.10 \pm 0.56) \log_{10}\) IU/mL, respectively, \(P < 0.0001)\]. The TDF group infants had lower rates of HBV-DNA positivity at birth than the controls \((6.15\%\ versus\ 31.48\%,\ respectively, P = 0.0003)\) and HBsAg positivity at 6 months old \((1.54\%\ versus\ 10.71\%,\ respectively, P = 0.0481)\).

In another study, tenofovir monotherapy was effective and safe when used as a rescue therapy in pregnant women resistant to lamivudine or telbivudine.

Based on the results of currently available clinical studies, the guidelines released by the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APSAL), and the Chinese Society of Hepatology recommend that in addition to combined active-passive immunization for newborns, antiviral therapy with tenofovir or telbivudine for pregnant women with high HBV viral loads, beginning...
at gestational week 28–32, is an effective and safe strategy for preventing MTCT.\textsuperscript{14,25,27,57}

CONFLICT OF INTEREST

None.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
2. Goldstein S, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329-1339.
3. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: The major impact of China. Hepatology. 2014;60:2099-2108.
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
5. Goyal A, Murray JM. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS One. 2014;9:e101043.
6. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34:1:51-83.
7. Jonas MM. Hepatitis B and pregnancy: An underestimated issue. Liver Int. 2009;29:133-139.
8. Chen CJ, Iloeje UH, Yang H. Long-term outcomes in hepatitis B: The REVEAL-HBV study. Clin Liver Dis. 2007;11:797-816.
9. Vodkin I, Patton H. Management of hepatitis B virus infection during pregnancy. Minerva Gastroenterol Dietol. 2014;60:205-214.
10. Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child transmission of HBV: Review of current clinical management and prevention strategies. Rev Med Virol. 2014;24:396-406.
11. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550-6557.
12. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009;200:39-47.
13. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009;122:3-4.
14. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5:297-318.
15. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization. http://apps.who.int/iris/bitstre
31. Singh AE, Plitt SS, Osiowy C, Surynticz K, Kouadjo E, Preiksaitis J, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat. 2011;18:468-473.

32. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: An Australian experience. Med J Aust. 2009;190:489-492.

33. Xu DZ, Yan YM, Choi BC, Xu JQ, Men K, Zhang JX, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: A case-control study. J Med Virol. 2002;67:20-26.

34. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18-e25.

35. Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B virus transmission. J Pediatric Infect Dis Soc. 2014;3:S7-S12.

36. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind placebo-controlled trial. Hepatology. 1983;3:135-141.

37. Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, et al. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol. 2003;9:1501-1503.

38. Xu WM, Cui YT, Wang L, Yang H, Liang QZ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: A multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.

39. Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11:402-409.

40. Brown RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012;57:953-959.

41. Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: Time to include selective antiviral prophylaxis? Lancet. 2012;379:2019-2021.

42. Cryer AM, Imperial JC. Hepatitis B in pregnant women and their infants. Clin Liver Dis. 2019;23:451-462.

43. Li J, Chang MS, Tran TT, Nguyen MH. Management of chronic hepatitis B in pregnancy. J Clin Gastroenterol. 2017;51:789-795.

44. Tosun S. Pregnancy and hepatitis B virus infection. Mediterr J Infect Microb Antimicrob. 2016;5:4.

45. Han L, Zhang H, Xie J, Zhang Q, Wang H, Cao G. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011;17:4321-4333.

46. Yu M, Jiang Q, Ji Y, Jiang H, Wu K, Ju L, et al. The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis. 2012;31:2211-2218.

47. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: Lack of potency and selection of resistance mutations. J Viral Hepat. 2014;21:809-817.

48. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215-1221.

49. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: A systematic review and meta-analysis. Virol J. 2012;9:185.

50. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-476.

51. Zhou Y, Zheng J, Pan H, Lu C. Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B. Chin J Hepatol. 2014;22:573-576. (in Chinese)

52. Wu Q, Huang H, Sun X, Pan M, He Y, Tan S, et al. Tenofovir prevents vertical transmission of hepatitis B virus from women with high viral loads: A prospective long-term study. Clin Gastroenterol Hepatol. 2015;13:1170-1176.

53. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19:9377-9382.

54. Grepup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-507.

55. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62:375-386.

56. Hu YH, Liu M, Yi W, Cao YJ, Cai HD. Tenofovir rescue therapy in pregnant females with chronic hepatitis B. World J Gastroenterol. 2015;21:2504-2509.

57. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.